Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

125 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Status of minimal residual disease determines outcome of autologous hematopoietic SCT in adult ALL.
Giebel S, Stella-Holowiecka B, Krawczyk-Kulis M, Gökbuget N, Hoelzer D, Doubek M, Mayer J, Piatkowska-Jakubas B, Skotnicki AB, Dombret H, Ribera JM, Piccaluga PP, Czerw T, Kyrcz-Krzemien S, Holowiecki J; Study Group for Adult ALL of the European Leukemia Net. Giebel S, et al. Bone Marrow Transplant. 2010 Jun;45(6):1095-101. doi: 10.1038/bmt.2009.308. Epub 2009 Oct 26. Bone Marrow Transplant. 2010. PMID: 19855438
Sequential recovery of NK cell receptor repertoire after allogeneic hematopoietic SCT.
Giebel S, Dziaczkowska J, Czerw T, Wojnar J, Krawczyk-Kulis M, Nowak I, Holowiecka A, Segatti A, Kyrcz-Krzemien S, Kusnierczyk P, Holowiecki J. Giebel S, et al. Bone Marrow Transplant. 2010 Jun;45(6):1022-30. doi: 10.1038/bmt.2009.384. Epub 2010 Feb 1. Bone Marrow Transplant. 2010. PMID: 20118994 Clinical Trial.
Outcome of HLA-matched related allogeneic hematopoietic stem cell transplantation for patients with acute leukemia in first complete remission treated in Eastern European centers. Better results in recent years.
Giebel S, Labopin M, Holowiecki J, Labar B, Komarnicki M, Koza V, Masszi T, Mistrik M, Lange A, Hellmann A, Vitek A, Pretnar J, Mayer J, Rzepecki P, Indrak K, Wiktor-Jedrzejczak W, Wojnar J, Krawczyk-Kulis M, Kyrcz-Krzemien S, Rocha V. Giebel S, et al. Ann Hematol. 2009 Oct;88(10):1005-13. doi: 10.1007/s00277-009-0719-5. Epub 2009 Mar 20. Ann Hematol. 2009. PMID: 19301005
Activating killer immunoglobulin-like receptor incompatibilities enhance graft-versus-host disease and affect survival after allogeneic hematopoietic stem cell transplantation.
Giebel S, Nowak I, Dziaczkowska J, Czerw T, Wojnar J, Krawczyk-Kulis M, Holowiecki J, Holowiecka-Goral A, Markiewicz M, Kopera M, Karolczyk A, Kyrcz-Krzemien S, Kusnierczyk P. Giebel S, et al. Eur J Haematol. 2009 Oct;83(4):343-56. doi: 10.1111/j.1600-0609.2009.01280.x. Epub 2009 Jun 2. Eur J Haematol. 2009. PMID: 19500138
Assessing the efficacy of allogeneic hematopoietic stem cells transplantation (allo-HSCT) by analyzing survival end points in defined groups of acute myeloid leukemia patients: a retrospective, multicenter Polish Adult Leukemia Group study.
Grosicki S, Holowiecki J, Kuliczkowski K, Skotnicki A, Hellmann A, Kyrcz-Krzemien S, Dmoszynska A, Sułek K, Kloczko J, Jedrzejczak WW, Warzocha K, Zdziarska B, Wierzbowska A, Pluta A, Komarnicki M, Giebel S. Grosicki S, et al. Am J Hematol. 2015 Oct;90(10):904-9. doi: 10.1002/ajh.24113. Am J Hematol. 2015. PMID: 26149802 Free article. Clinical Trial.
Impact of conditioning with TBI in adult patients with T-cell ALL who receive a myeloablative allogeneic stem cell transplantation: a report from the acute leukemia working party of EBMT.
Cahu X, Labopin M, Giebel S, Aljurf M, Kyrcz-Krzemien S, Socié G, Eder M, Bonifazi F, Bunjes D, Vigouroux S, Michallet M, Stelljes M, Zuckerman T, Finke J, Passweg J, Yakoub-Agha I, Niederwieser D, Sucak G, Sengeløv H, Polge E, Nagler A, Esteve J, Mohty M; Acute Leukemia Working Party of EBMT. Cahu X, et al. Bone Marrow Transplant. 2016 Mar;51(3):351-7. doi: 10.1038/bmt.2015.278. Epub 2015 Nov 30. Bone Marrow Transplant. 2016. PMID: 26618548
Could cytogenetics and minimal residual disease replace conventional risk criteria in adults with Ph-negative acute lymphoblastic leukaemia?
Giebel S, Krawczyk-Kulis M, Kyrcz-Krzemien S, Haus O, Jagoda K, Piatkowska-Jakubas B, Paluszewska M, Seferynska I, Chrobok A, Stella-Holowiecka B, Kielbinski M, Holowiecki J. Giebel S, et al. Br J Haematol. 2009 Mar;144(6):970-2. doi: 10.1111/j.1365-2141.2008.07540.x. Epub 2008 Dec 12. Br J Haematol. 2009. PMID: 19120362 Free article. No abstract available.
The early reduction of leukemic blasts in bone marrow on day 6 of induction treatment is predictive for complete remission rate and survival in adult acute myeloid leukemia; the results of multicenter, prospective Polish Adult Leukemia Group study.
Grosicki S, Holowiecki J, Giebel S, Kyrcz-Krzemien S, Kuliczkowski K, Kielbinski M, Skotnicki AB, Piatkowska-Jakubas B, Hellmann A, Wierzbowska A, Stella-Holowiecka B, Zdziarska B, Calbecka M. Grosicki S, et al. Am J Hematol. 2011 May;86(5):437-9. doi: 10.1002/ajh.21996. Epub 2011 Apr 4. Am J Hematol. 2011. PMID: 21465518 Free article. Clinical Trial.
Cladribine, but not fludarabine, added to daunorubicin and cytarabine during induction prolongs survival of patients with acute myeloid leukemia: a multicenter, randomized phase III study.
Holowiecki J, Grosicki S, Giebel S, Robak T, Kyrcz-Krzemien S, Kuliczkowski K, Skotnicki AB, Hellmann A, Sulek K, Dmoszynska A, Kloczko J, Jedrzejczak WW, Zdziarska B, Warzocha K, Zawilska K, Komarnicki M, Kielbinski M, Piatkowska-Jakubas B, Wierzbowska A, Wach M, Haus O. Holowiecki J, et al. J Clin Oncol. 2012 Jul 10;30(20):2441-8. doi: 10.1200/JCO.2011.37.1286. Epub 2012 Apr 16. J Clin Oncol. 2012. PMID: 22508825 Clinical Trial.
125 results